Abstracts tagged "Comorbidity"

Abstract Number: 0864 • ACR Convergence 2024
Obesity Subtypes and Trajectories of Functional Change After 7-years of Follow-up: The Multicenter Osteoarthritis (MOST) Study
Kristine Godziuk¹, Sarah Tilley², mike LaValley³, Michael Nevitt⁴, C.E. Lewis⁵, James Torner⁶ and Tuhina Neogi², ¹University of Alberta, Edmonton, AB, Canada, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴UCSF, Orinda, CA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Iowa, Iowa City
Background/Purpose: People with knee osteoarthritis (OA) and obesity (i.e. BMI ≥30kg/m2) have poorer function than those without obesity. However, function is not uniform among people…
Abstract Number: 1909 • ACR Convergence 2024
Racial Disparities in Ocular Complications of Systemic Rheumatic Diseases: A Retrospective Cross-Sectional Study
Insa Mannstadt¹, Yiyuan Wu² and Bella Mehta³, ¹Columbia University VP&S, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: While systemic rheumatic diseases, including Sjogren's syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and spondyloarthropathies, are known to have severe ophthalmologic manifestations, there…
Abstract Number: 0975 • ACR Convergence 2024
Prevalence and Management of Patients with Comorbidities and Frailty in New Onset Polymyalgia Rheumatica
Sebastian E. Sattui¹, FRANK HARTMUT DR. BUTTGEREIT², Merav Lidar³, Kerri Ford⁴, Stefano Fiore⁵, Lita Araujo⁴, Timothy Beukelman⁶, Fenglong Xie⁷ and Jeffrey Curtis⁸, ¹University of Pittsburgh, Pittsburgh, PA, ²Charité University Medicine Berlin, Berlin, Germany, ³Rheumatology Unit, Sheba Medical Center, Tel Hashomer, Israel, ⁴Sanofi, Cambridge, MA, ⁵Sanofi, Bridgewater, NJ, ⁶Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: PMR, a common inflammatory rheumatic disease in older adults, is primarily treated with glucocorticoids (GC). A high comorbidity burden in PMR may increase the…
Abstract Number: 1912 • ACR Convergence 2024
Greater Glucocorticoid and Less Biologic/Targeted Therapy Use in Midwest PsA Patients Despite Prevalent Comorbidity
Brittany Banbury¹, Sharon Dowell², Christopher Jenkins³, Emily Holladay⁴, Cassie Clinton⁵, Fenglong Xie⁵, Jingyi Zhang⁵, Grace Wright⁶, Jeffrey Curtis⁷ and Gail Kerr⁸, ¹Mount Sinai Beth Israel, Brooklyn, NY, ²NEA Baptist Memorial Hospital, JONESBORO, AR, ³Medstar Georgetown University Hospital, Washington, DC, ⁴University of Alabama at Birmingham, Edmond, OK, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Grace C Wright MD PC, New York, NY, ⁷University of Alabama at Birmingham, Hoover, AL, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: There is regional variation in the clinical characteristics, treatment, and outcomes of patients with inflammatory arthritis in the US. Despite a higher reported prevalence of…
Abstract Number: 1004 • ACR Convergence 2024
Predictors of Post-acute Sequelae of COVID-19 in Patients with Rheumatoid Arthritis: A Retrospective Analysis of a Large Health System in the Midwestern United States
Ernesto Lopez Castillo¹ and Jeffrey Ording², ¹University of Colorado, Denver, CO, ²Advocate Illinois Masonic Medical Center, Chicago, IL
Background/Purpose: Evidence suggests that patients with autoimmune diseases or immunosuppressive conditions have a higher risk of poor outcomes related to Coronavirus disease 2019 (COVID-19) infection.…
Abstract Number: 1986 • ACR Convergence 2024
Disease Flare Following Immune Checkpoint Inhibition in Patients with Cancer and Preexisting Vasculitis
Juan Sevillano¹, Yixuan Zhou², Juan Ruiz³, Noha Abdel-Wahab⁴ and Maria Suarez-Almazor¹, ¹MD Anderson Cancer Center, Houston, TX, ²Baylor College of Medicine, Houston, ³MD Anderson, Houston, TX, ⁴University of Texas MD Anderson Cancer Center, houston, TX
Background/Purpose: Immune checkpoint inhibitors (ICI) are effective therapies for patients with cancer, but they often cause immune-related adverse events (irAE). There is limited data on…
Abstract Number: 1097 • ACR Convergence 2024
CERT Score as a Potential Tool to Predict Cardiovascular Risk in Gout and Hyperuricemia
Blanka Stiburkova¹, Aleš Kvasnička², Barbora Pisklakova², Jakub Rozhon², Karel Pavelka³ and David Friedecky², ¹Institute of Rheumatology, Prague, Czech Republic and Department of Paediatrics and Inherited Metabolic Disorders, 1st Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic, Prague, Czech Republic, ²Laboratory for Inherited Metabolic Disorders, Department of Clinical Biochemistry, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic, Olomouc, Czech Republic, ³Institute of Rheumatology and Charles University, Praha, Czech Republic
Background/Purpose: Asymptomatic hyperuricemia and gout are two clinical conditions associated with a high risk of cardiovascular events and mortality. Recent data suggest that the number…
Abstract Number: 2021 • ACR Convergence 2024
The Dual Benefits of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Nephrolithiasis and Gout Flares Among Gout Patients with Type 2 Diabetes: New User, Active Comparator Target Trial Emulation Studies
Natalie McCormick¹, Chio Yokose², Leo Lu³, Deborah Wexler¹, J. Antonio Avina-Zubieta⁴, Mary A. De Vera⁵, saiajay chigurupati¹, Kiara Tan¹, Chixiang Chen⁶, Rozalina McCoy⁶, Gary Curhan⁷ and Hyon K. Choi⁸, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁵University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ⁶University of Maryland, School of Medicine, Baltimore, MD, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Massachusetts General Hospital, Lexington, MA
Background/Purpose: Nephrolithiasis and gout are both common, extremely painful conditions which frequently coexist, along with type 2 diabetes (T2D). Sodium-glucose cotransporter-2 inhibitors (SGLT2i), first approved…
Abstract Number: 1101 • ACR Convergence 2024
The Contemporary Prevalence of Comorbid Gout and Chronic Kidney Disease, Two Common Conditions with High Morbidity, in the US General Population
Chio Yokose¹, Leo Lu², Sharan Rai³, Natalie McCormick³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Waltham, MA, ²Arthritis Research Canada, Vancouver, BC, Canada, ³Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Gout and chronic kidney disease (CKD) are both common conditions which are associated with high morbidity and mortality and often coexist. We sought to…
Abstract Number: 2024 • ACR Convergence 2024
Serum Urate Change Among Patients with Gout Treated with Anti-Hypertensive Medications: A Comparative Effectiveness Analysis
Chio Yokose¹, saiajay chigurupati², Bohang Jiang², Kiara Tan², Natalie McCormick² and Hyon K. Choi³, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Hypertension is the most common comorbidity among patients with gout, with a prevalence of nearly 75% among patients with gout. Losartan and calcium channel…
Abstract Number: 1116 • ACR Convergence 2024
Understanding the Prevalence, In-Hospital Mortality and Readmission Rates Amongst Pulmonary vs Cardiac Sarcoidosis Patients: Insights from a Nationwide Registry
Shivang Chaudhary¹, Kaushik Gokul¹, Kishan Patel², Simran Bhimani³, Yash Deshpande³, Adam Kilian¹, Ravi Nayak¹, Deana Mikhalkova¹ and Chaitanya Rojulpote¹, ¹Saint Louis University, St. Louis, MO, ²Riverside Community Hospital, Riverside, CA, ³The Wright Center for graduate medical education, Scranton, PA
Background/Purpose: Sarcoidosis is a complex, multisystemic disorder predominantly affecting the pulmonary system but can also involve extra-pulmonary organs such as the heart. Mortality in sarcoidosis…
Abstract Number: 2110 • ACR Convergence 2024
Association Between Symptomatic Knee Osteoarthritis and Blood Glucose Control in Persons with Type 2 Diabetes
Lauren King¹, Alanna Weisman¹, Baiju Shah¹, Robert Goldberg¹, Amish Parikh², Ian Stanaitis³, Rosane Nisenbaum⁴, Esther Waugh¹, Lorraine Lipscombe¹ and Gillian Hawker¹, ¹University of Toronto, Toronto, ON, Canada, ²Trillium Health Partners, Toronto, ON, Canada, ³Women's College Hospital, Toronto, ON, Canada, ⁴Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, ON, Canada
Background/Purpose: There is a high prevalence of knee osteoarthritis (OA) in people with type 2 diabetes (T2D), and knee OA increases risk for diabetes complications…
Abstract Number: 1216 • ACR Convergence 2024
Subcutaneous Methylnaltrexone Treatment of Opioid-Induced Constipation in Adults with Rheumatic Conditions
Larry Moreland¹, Rowe Brookfield² and Adam Laitman², ¹University of Colorado, Denver, CO, ²Salix Pharmaceuticals, Bridgewater, NJ
Background/Purpose: In patients taking opioid analgesics, opioid-induced constipation (OIC) is estimated to affect between 41% to 80% of patients and is caused by peripheral mu-opioid…
Abstract Number: 2171 • ACR Convergence 2024
A Qualitative Exploration of Oral Healthcare Needs Amongst Canadian Patients with Rheumatic Diseases and Their Providers
Chrysi Stavropoulou¹, Corrie Billedeau², Jennifer Protudjer¹ and Carol Hitchon¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²NA, Winnipeg, MB, Canada
Background/Purpose: Patients with autoimmune rheumatic diseases (RDs) have a high prevalence of oral manifestations and/or oral side effects from immunomodulatory medications. These factors combined with…
Abstract Number: 1239 • ACR Convergence 2024
Innovative Patient Empowerment: Evaluating the Effect of a Physician-created Educational Video and To-do Lists on Promoting Preventive Health Measures in Rheumatic Disease Patients
Vanessa Bartsch¹, Basel Habboub², Kathrin Standfest¹, Johannes Knitza³, Georg Schett⁴ and Axel Hueber², ¹Division Rheumatology, Klinikum Nuernberg, Nuernberg, Germany, ²Klinikum Nuernberg, Nuernberg, Germany, ³Institute for Digital Medicine, Philipps-University Marburg and University Hospital of Giessen and Marburg, Marburg, Germany, ⁴Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Patients with inflammatory rheumatic diseases (IRDs) are at higher risk for malignancies and infections. Effective management strategies for these comorbidities are urgently needed. We…

1
2
3
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].